Research progress of drug resistance mechanisms to temozolomide in glioblastoma: A narrative review
Glioblastoma multiforme (GBM) is the most common malignant tumor in the adult central nervous system, and surgery combined with radiotherapy and chemotherapy represents the main treatment regimens. Temozolomide (TMZ) is currently the first-line chemotherapeutic agent used in GBM therapy and is widel...
Main Author: | Allen Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
Series: | Glioma |
Subjects: | |
Online Access: | http://www.jglioma.com/article.asp?issn=2589-6113;year=2022;volume=5;issue=3;spage=81;epage=86;aulast=Lu |
Similar Items
-
Transcriptomic Profiling of DNA Damage Response in Patient-Derived Glioblastoma Cells before and after Radiation and Temozolomide Treatment
by: Mathew Lozinski, et al.
Published: (2022-04-01) -
Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity
by: Fangting You, et al.
Published: (2023-06-01) -
Characterization of Temozolomide Resistance Using a Novel Acquired Resistance Model in Glioblastoma Cell Lines
by: Yuan Zhu, et al.
Published: (2022-04-01) -
Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil
by: Karoline Almeida Lima, et al.
Published: (2023-04-01) -
Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin
by: Shao-Wei Feng, et al.
Published: (2022-07-01)